| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Cancer Research | 39 / 233 | 83rd | Q1 |
Compare journals
Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Neoplasia (United States)
Neoplasia (United States) is Scopus-indexed (Q1, CiteScore 11.4), WoS SCIE, DOAJ. Published by Elsevier Inc..
Checked against the index lists dated .
ISSN 1476-5586Verify ISSN ↗1522-8002Verify ISSN ↗
Publisher: Elsevier Inc.
Cost to publish: Checking DOAJ for article charges…
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Quick answers
Is Neoplasia (United States) indexed in Scopus?
Yes — actively indexed in Scopus, coverage 1999–present, best quartile Q1, CiteScore 11.4.
What quartile is Neoplasia (United States) in Scopus?
Neoplasia (United States) is Q1 in Cancer Research (rank 39 of 233), by CiteScore 2025.
What is the impact factor of Neoplasia (United States)?
Neoplasia (United States) is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 11.4, which places it in quartile Q1 at the 83rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 2.284, quartile Q1, with an H-index of 151.
How much does it cost to publish in Neoplasia (United States)?
The publisher lists an article processing charge of about US$3,530 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Who publishes Neoplasia (United States) and what is its ISSN?
Neoplasia (United States) is published by Elsevier Inc. Its print ISSN is 1476-5586 and its online ISSN is 1522-8002.
Is Neoplasia (United States) in Web of Science?
Yes — indexed in the Science Citation Index Expanded.
Is Neoplasia (United States) open access?
Yes — it is an open-access journal, listed in DOAJ.
How well cited is Neoplasia (United States)? — open metrics via OpenAlex
Neoplasia (United States) has an h-index of 159 and a 2-year mean of 4.95 citations per paper (OpenAlex). Its Scopus CiteScore is 11.4, quartile Q1. On 2-year citations it ranks #49 of 229 Scopus journals in Cancer Research.
Neoplasia (United States) published 137 papers in 2025; its busiest recent year was 2024 with 151. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
Who publishes in Neoplasia (United States)? — latest 100 articles, 2025–2026
In its latest 100 research articles (2025–2026), authors are most often from China (40.3%), United States (24.3%) and Japan (4.8%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Are there integrity warnings for Neoplasia (United States)? — indicators, not proof of misconduct
Scopus status: Active. 9 retracted papers are recorded (3.1 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
- Scopus statusActive
- Retracted papers 9 · 3.1 per 1,000 papers
- Problematic Paper Screener flags None flagged
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Official sources & links
Community experience: reader comments on this journal
Related journals
8 journalsIndex data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.